Thermo Fisher Scientific Inc.
General ticker "TMO" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $196.8B (TTM average)
Thermo Fisher Scientific Inc. follows the US Stock Market performance with the rate: 18.1%.
Estimated limits based on current volatility of 1.3%: low 607.54$, high 623.01$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-06-15, amount 0.47$ (Y0.29%)
- Total employees count: 125000 (0.0%) as of 2025
- US accounted for 50.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Market demand decline, Economic downturns and volatility, Currency fluctuations, Trade tariffs, Supply chain disruptions
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [527.47$, 711.72$]
- 2026-12-31 to 2027-12-31 estimated range: [567.03$, 760.83$]
Financial Metrics affecting the TMO estimates:
- Negative: with PPE of 25.4 at the end of fiscal year the price was high
- Positive: 15.80 < Operating profit margin, % of 17.38
- Positive: 2.37 < Operating cash flow per share per price, % of 3.58
- Positive: 42.26 < Shareholder equity ratio, % of 48.40 <= 49.86
- Positive: 5.14 < Return on assets ratio (scaled to [-100,100]) of 5.77
- Positive: -16.84 < Industry operating profit margin (median), % of -16.21
- Positive: Inventory ratio change, % of 1.02 <= 1.34
- Positive: -2.60 < Investing cash flow per share per price, % of -1.85
- Negative: 0.33 < Interest expense per share per price, % of 0.65
Short-term TMO quotes
Long-term TMO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $42,857.00MM | $42,879.00MM | $44,556.00MM |
| Operating Expenses | $35,998.00MM | $35,542.00MM | $36,810.00MM |
| Operating Income | $6,859.00MM | $7,337.00MM | $7,746.00MM |
| Non-Operating Income | $-561.00MM | $-300.00MM | $-438.00MM |
| Interest Expense | $1,375.00MM | $1,390.00MM | $1,419.00MM |
| R&D Expense | $1,337.00MM | $1,390.00MM | $1,397.00MM |
| Income(Loss) | $6,298.00MM | $7,037.00MM | $7,308.00MM |
| Taxes | $284.00MM | $657.00MM | $547.00MM |
| Other Income(Loss) | $-59.00MM | $-42.00MM | $-40.00MM |
| Net Income(Loss)* | $5,995.00MM | $6,335.00MM | $6,704.00MM |
| Stockholders Equity | $46,735.00MM | $49,584.00MM | $53,407.00MM |
| Inventory | $5,088.00MM | $4,978.00MM | $5,425.00MM |
| Assets | $98,726.00MM | $97,321.00MM | $110,343.00MM |
| Operating Cash Flow | $8,406.00MM | $8,667.00MM | $7,818.00MM |
| Capital expenditure | $1,479.00MM | $1,400.00MM | $1,525.00MM |
| Investing Cash Flow | $-5,142.00MM | $-5,841.00MM | $-4,047.00MM |
| Financing Cash Flow | $-3,622.00MM | $-6,792.00MM | $1,801.00MM |
| Earnings Per Share** | $15.53 | $16.58 | $17.83 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.